A phase I study of TRC105 anti-endoglin ( CD 105) antibody in metastatic castration-resistant prostate cancer

OBJECTIVE: TRC105 is a chimeric immunoglobulin G1 monoclonal antibody that binds endoglin (CD105). This phase I open-label study evaluated the safety, pharmacokinetics and pharmacodynamics of TRC105 in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: Patie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BJU Int
Main Authors: Karzai, Fatima H., Apolo, Andrea B., Cao, Liang, Madan, Ravi A., Adelberg, David E., Parnes, Howard, McLeod, David G., Harold, Nancy, Peer, Cody, Yu, Yunkai, Tomita, Yusuke, Lee, Min-Jung, Lee, Sunmin, Trepel, Jane B., Gulley, James L., Figg, William D., Dahut, William L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6596291/
https://ncbi.nlm.nih.gov/pubmed/25407442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bju.12986
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados